Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of RP, Oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): Results of the AIO KRK 0207 phase III study. 6. Juni 2014 Hegewisch-Becker, S., Arnold, D., Lerchenmüller, C., Killing, B., Depenbusch, R., Steffens, C.-C., Al-Bartan, S.-E., Lange, T., Dietrich, G., Stoehlmacher, J., Reinacher-Schick, A., Tannapfel, A., Quidde, J., Hinke, A., Schmoll, H.-J., Graeven, U., 2014. Oncol Res Treat 37 (Suppl.5)(V327), 99 doi:10.1159/000368945 Abstract Bendamustine-based first line therapy in chronic lymphocytic leukemia (CLL) in routine clinical practice: Interim analysis of the German non-interventional study Be-CeLL1st. Bruch, H.-R., Aldaoud, A., Klausmann, M., Hansen, R., Losem, C., Frank, M., Straßl, L., Ruffert, K., 2014. Haematologica 99 (suppl 1) (PB1504). Weiterlesen Real-life treatment of patients with advanced pancreatic cancer in Germany – data from the clinical registry pancreatic cancer (TPK). Hegewisch-Becker, S., Hofheinz, R.-D., Hartmann, H., Kopfmann, S., Marschner, N., 2014. Oncol Res Treat 37(Suppl.5)(P274), 86. doi:10.1159/000368945 Abstract… Weiterlesen